CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field.
The podcast is a timely update on the US pharma field, more specifically regarding the drug market, including the price negotiations and giving an overview of the Inflation Reduction Act, and the consequences these changes will have on the industry across the USA and the globe.
James Manser is the President of Pantheon Strategies LLC, a consulting company focused on policy development and messaging to policymakers. James brings over 20 years of government experience having worked on campaigns and in executive staff positions spanning local, state, and federal government. Most of his career has been focused on advancing economic development in the pharmaceutical industry and access to innovative therapies for patients. Previously James served as Head of Office of the Government Affairs department for a global pharmaceutical company. In this role he was responsible for all government affairs activity as well as managing the Patient Assistance Program, serving as chair of the Political Action Committee, and serving as chair of the Corporate Philanthropic Committee.
The podcast will aim to cover the recent changes in legislature around drug pricing in the USA, and what this means for the global pharma market, as well as the impact it will have on the US population in terms of access to medicine. The price negotiations with Medicare are targeting medications used in the treatment of many chronic diseases such as cardiovascular disease and diabetes. We will take a look at what this means for people with chronic disease, and conversely the impact on the individual pharma companies and then more widely, on innovation in the industry.
James was able to give such great context and insights to the conversation, remarking on different perspectives that all come into play, which was extremely valuable and real food for thought!
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News 3 ways ChatGPT will impact pharma marketing teams
What does the rise of AI-powered chatbots such as ChatGPT and GPT-4 mean for pharma marketeers?
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance